Results 321 to 330 of about 532,411 (388)

Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2. [PDF]

Neuropediatrics
Priglinger CS, Courage C, Lotz-Havla AS, Gerhardt M, Ehrt O, Kurz M, Pudritz H, Rudolph G, Jackson CB, Maier EM.   +9 more
europepmc   +1 more source

Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys. [PDF]

Orphanet J Rare Dis
Revel-Vilk S, Ramaswami U, Pintos-Morell G, Hughes D, Nicholls K, Reisin R, Giugliani R, Goker-Alpan O, Istaiti M, Gill A, Scarpa M, Botha J.   +11 more
europepmc   +1 more source

Enzyme Replacement Therapy in Mucopolysaccharidosis Type VII: A Three-Year Clinical Outcome Study of the First Taiwanese Case. [PDF]

Diagnostics (Basel)
Lee CL, Chuang CK, Chiu HC, Chang YH, Tu YR, Lo YT, Lin HY, Lin SP.   +7 more
europepmc   +1 more source

Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry Disease. [PDF]

Kidney Dis (Basel)
Yang J, Wei Z, Ni H, Wu Q, Peng S, Shi W, Wang X, Yang Y, Jiang J, Cao J, Wang Y, Zhang L, Zhang A, Zhang X, Wang B.   +14 more
europepmc   +1 more source

Immune response to enzyme replacement therapy in MPS I and GSD II patients / Revecca Kakavanos.

, 2006
Revecca Kakavanos
openalex   +1 more source

Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down-Regulation of Mannose-6-Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy. [PDF]

J Am Heart Assoc
Frustaci A, Verardo R, Magnocavallo M, Frustaci E, Russo MA, Chimenti C.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Enzyme replacement therapy.

Survey of Ophthalmology, 2019
A. Moore
semanticscholar   +3 more sources